RU486 (MIFEPRISTONE): Mechanisms of Action and Clinical Uses
Tóm tắt
▪ Abstract RU486 (mifepristone) has proved to be a remarkably active antiprogesterone and antiglucocorticosteroid agent in human beings. The mechanism of action involves the intracellular receptors of the antagonized hormones (progesterone and glucocorticosteroids). At the molecular level, the most important features are high binding affinity to the receptor, interaction of the phenylaminodimethyl group in the 11β-position with a specific region of the receptor binding pocket, and RU486-induced transconformation differences in the ligand-binding domain. These particularities have consequences at different steps of the receptor function as compared with agonists. However, the reasoning cannot be limited to the RU486-receptor interaction, and, for instance, there is the possibility of a switch from antagonistic property to agonist activity, depending on the intervention of other signaling pathways. It would be desirable to have derivatives with only one of the two antagonistic properties (antiprogestin, antiglucocorticosteroid) in spite of similarities between steroid structures, receptors involved, and responsive machineries in target cells. Clinically, the RU486-plus-prostaglandin method is ready to be used on a large scale and is close to being as convenient and safe as any medical method of abortion may be. The early use of RU486 as a contragestive as soon as a woman fears a pregnancy she does not want will help to defuse the abortion issue. Research should now be conducted to define an efficient and convenient contraceptive method with RU486 or other antiprogestins. The usefulness of RU486 for obstetric indications, including facilitation of difficult delivery, has to be assessed rapidly. Gynecologic trials, particularly in leiomyomata, should also be systematically continued. The very preliminary results obtained with tumors, including breast cancers, indicate that further studies are necessary.
Từ khóa
Tài liệu tham khảo
Baulieu E-E. 1993.RU486—A decade on, today and tomorrow.InClinical Applications of Mifepristone RU 486 and Other Antiprogestins, ed. MS Donalson, D Dorflinger, SS Brown, LZ Benet, pp. 71–119. Washington: Natl. Acad. Inst. Med.
Herrmann WL, 1982, C. R. Acad. Sci. Paris, 294, 933
Baulieu EE. 1985.RU486: an antiprogestin steroid with contragestive activity in women.InThe Antiprogestin Steroid RU486 and Human Fertility Control, ed. EE Baulieu, SJ Segal, pp. 1–25. New York: Plenum
Philibert D, Costerousse G, Gaillard-Moguilewsky M, et al. 1991.From RU38486 towards dissociated antiglucocorticoid and antiprogesterone.InAntihormones in Health and Disease, ed. MK Agarwal, 19:1–17. Basel: Karger
Chrousos GP, Lane L, Nieman LK, et al. 1989.Clinical applications of RU 486, a prototype glucocorticoid and progestin antagonist.InAdrenal and Hypertension: From Cloning to Clinic, ed. F Mantero, BA Scoggins, R Takeda, et al, pp. 273–84. New York: Raven
Baulieu EE, Catelli MG. 1989.Steroid hormone receptors and heat shock protein Mr 90,000 (hsp90): a functional interaction?InStress-Induced Proteins, ed. ML Pardue, JR Feramisco, S Lindquist, pp. 203–19. New York: Liss
Lebeau MC, Binart N, Cadepond F, et al. 1993.Steroid receptor associated proteins: heat shock protein 90 and p59 immunophilin.InSteroid Hormone Receptors: Basic and Clinical Aspects, ed. VK Moudgil, pp. 261–80. Boston: Birkhäuser
Saatcioglu F, 1994, Cancer Biol., 5, 347
Aubény E, 1991, C. R. Acad. Sci. Paris, 312, 539
Heard M, 1992, Lancet, 304, 914
Jost A, 1986, C. R. Acad. Sci. Paris, 303, 281
Lim BH, 1990, Lancet, 2, 257
1990, Am. J. Obstet. Gynecol., 160, 45
Frydman R, 1992, Obst. Gynecol., 80, 972
Baulieu EE. 1991. InThe Abortion Pill, pp. 11–216. New York: Simon & Schuster
Bosc MJ, Germain G, Nicolle A, et al. 1985.The use of antiprogesterone compound RU486 to control timing of parturition in rats.InThe Antiprogestin Steroid RU486 and Human Fertility Control, ed. EE Baulieu, SJ. Segal, pp. 69–70. New York: Plenum
Herrmann WL, Schindler AM, Wyss R1985.Effects of the antiprogesterone RU486 in early pregnancy and during the menstrual cycle.InThe Antiprogestin Steroid RU486 and Human Fertility Control, ed. EE Baulieu, SJ Segal, pp. 179–98. New York: Plenum
Klijn JAGM, 1989, Cancer Res., 49, 2851
Romieu G, 1987, Bull. Cancer, 74, 455
Haak HR, 1990, Lancet, 2, 124
Kling MA, 1989, Psychopharmacol. Bull., 25, 466
Kling MA, 1989, Psychopharmacol. Bull., 25, 466
Grünfeld JP, 1987, Adv. Nephrol., 16, 53
Grünfeld JP, 1988, Kidney Int., 34, 24
Okada S, 1992, Am. Physiol. Soc., 262, 51106
Gruol DJ, 1994, Cancer Res., 54, 3088
Hospital M, 1972, Mol. Pharmacol., 8, 438